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Abstract The objectives of this study were: (1) to assess
relative frequency of migraine in multiple sclerosis (MS)
patients using the validated self-administered diagnostic
questionnaire, and to compare the migraine rates in MS
outpatients to age- and gender-matched historical popula-
tion controls; (2) to compare clinical and radiographic
characteristics in MS patients with migraine and headache-
free MS patients. We conducted a cross-sectional study to
assess the demographic profiles, headache features and
clinical characteristics of MS patients attending a MS clinic
using a questionnaire based on the American Migraine
Prevalence and Prevention (AMPP) study. We compared
the relative frequency of migraine in MS clinic patients and
AMPP cohort. We also compared clinical and radiographic
features in MS patients with migraine to an MS control
group without headache. Among 204 MS patients, the
relative frequency of migraine was threefold higher than in
population controls both for women [55.7 vs. 17.1%;
prevalence ratio (PR) = 3.26, p \ 0.001] and men (18.4
vs. 5.6%; PR = 3.29, p \ 0.001). In a series of logistic
regression models that controlled for age, gender, disease
duration, b-interferon use, and depression, migraine in MS
patients was significantly associated (p \ 0.01) with tri-
geminal and occipital neuralgia, facial pain, Lhermitte’s
sign, temporomandibular joint pain, non-headache pain and
a past history of depression. Migraine status was not sig-
nificantly associated with disability on patient-derived
disability steps scale or T2 lesion burden on brain MRI.
Migraine is three-times more common in MS clinic
patients than in general population. MS–migraine group
was more symptomatic than the MS–no headache group.
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Introduction
The possibility of a link between migraine and multiple
sclerosis (MS) was recognized more than half a century
ago when Compston and McAlpine [1] reported that 2% of
MS patients developed migraines within 3 months of their
first relapse. The association between migraine and MS
was observed in two case–control series [2, 3] that predated
introduction of the International Classification of Headache
Disorders (ICHD-2) [4]. Four of five subsequent controlled
studies [2, 3, 5–7] and several uncontrolled studies that
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used ICHD-2 criteria confirmed that headache prevalence
is elevated among persons with MS [8–11]. Among these is
a population-based study from Sicily that reported a dou-
bling of headache prevalence in MS patients compared to
controls [5]. Only one study did not detect a statistically
significant difference in headaches between MS patients
and historical controls [7], possibly due to very high
prevalence of primary headaches in the local population.
It is not clear if the association between headache and
MS is specific to migraine. Po¨llmann et al. [10, 11]
observed that among interferon-treated MS patients,
migraine was predominant headache type while tension-
type headache predominated among those not treated with
interferon.
The question of whether co-existing migraine in an MS
patient affects the symptomatology, comorbidity, and
course of MS has not been well explored. An observed
association between presence of migraine and relapsing–
remitting course of MS [3, 9], has not been reported in all
studies. As some comorbidities have recently been shown
to be risk factors for increased MS severity [12] this issue
acquires special relevance.
The objectives of our study were threefold: (1) to
compare the relative frequency of migraine in an MS
specialty clinic and in population controls using the vali-
dated self-administered diagnostic questionnaire from the
American Migraine Prevalence and Prevention (AMPP)
study [13]; (2) to compare the ‘MS–migraine group’ with
the ‘MS–no headache’ group with respect to symptom
profile and co-existing diagnoses, with special attention to
psychiatric disorders, which are known to be more frequent
among migraineurs [14–16]; (3) to compare radiographic
(MRI) markers of disease in MS migraineurs and in
headache-free MS.
Methods
NYU-MS Care Center serves an ethnically and socio-
economically diverse population of over 2,400 MS patients
in the greater New York area. Eligible patients were over
18 years of age, had diagnosis of MS by the revised
McDonald criteria and fluent understanding of written
English. They completed a questionnaire at the time of
routinely scheduled clinic visits over a 3-month period
from October 2006 to January 2007. The study was
approved by Institutional Review Board of New York
University Medical Center.
We aimed to collect over 200 responses as this would
allow us to separate observed prevalence of migraines from
the historical controls (13%) [17], if the observed preva-
lence is less than 9.4% or more than 19.5%, with confi-
dence intervals on prevalence estimates of [95%.
Questions on headache frequency and characteristics
were identical to those in the validated diagnostic ques-
tionnaire included in the American Migraine Prevalence
and Prevention (AMPP) study, the largest epidemiological
study of migraine to date. This questionnaire assesses the
characteristics of up to three patient-identified headaches
and has a sensitivity of 100% and specificity of 82% for
an ICHD-2-based gold standard diagnosis of migraine
[17]. Diagnoses were assigned using identical data and
procedures in the NYU-MS Care Center and in the AMPP
study [13]. Prevalence of various headaches in MS
patients from the NYU-MS Care Center was compared to
that in AMPP cohort. Migraine severity was assessed
using the validated Migraine Disability Assessment
(MIDAS) tool [18]. Comorbidities were assessed in the
MS patients using the same instruments as in the AMPP-
Patient Health Questionnaire (PHQ-9) for depression,
Patient Health Questionnaire (PHQ) for anxiety and
Allodynia Symptom Check list for allodynia. Additional
questions, not included in the AMPP, addressed MS
duration and treatment, fatigue (Fatigue Severity Scale),
daytime sleepiness (Epworth Sleepiness Scale), and
brainstem and visual symptoms using questions developed
specifically for this study. We also assessed rates of
‘episodic neurologic dysfunction’ (END) defined as ‘a
new neurological symptom, or significant worsening of
preexisting symptom(s) of more than 24 h in duration’.
Although END definition mirrors that of MS relapse in
the McDonald’s criteria, we use the former term because
our patients were not necessarily examined at the time of
their new or worsening symptoms and so we were unable
to corroborate patients’ report of worsening with objective
findings on examination and exclude possibility of inter-
current infection/stressor. Thus, ENDs could represent
bona fide relapses or ‘pseudo-exacerbations’ (unmasking
of previous deficits due to physiological or psychological
stressors). The definition of END was provided in the
questionnaire, along with a list of typical neurologic
symptoms reported during an MS relapse. Patients were
asked to estimate the number of ENDs they had experi-
enced over the previous year. Patients’ disability level
was assessed with Patient-Derived Disability Steps. PDDS
is a surrogate measure of the Expanded Disability Status
Scale (EDSS) and correlates well with the EDSS in both
cross-sectional and longitudinal assessments [19].
Brain MRIs completed on participating patients within
2 years of the survey were reviewed by an MS neurologist
and an expert in MS neuroradiology blind to the patients’
clinical history. MRI scans included T2-weighted, and pre-
and post-contrast T1-weighted sequences. All scans were
done at 1.5-T magnet machine with exception of five scans
that were done at 3-T magnet and two scans at 0.6-T
magnet. The number of hyperintense lesions on brain
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T2-weighted scans, hypointense lesions on T1-weighted
scans and gadolinium-enhancing lesions on post-contrast
T1-weighted sequence were recorded, as were the number
of T2 hyperintense lesions in periventricular white matter,
subcortical white matter, corpus callosum, brainstem and
basal ganglia. Lesions involving a given structure were
considered as separate, and therefore counted individually,
if regions of normal signal intensity were present between
slices.
Group comparisons were carried out using t tests for
continuous variables and Chi-squared test for differences in
proportions. A series of logistic regression models were
used to assess the association of migraine on a variety of
outcome measures in persons with MS. The main predictor
variable was migraine status. We controlled for age, gen-
der, disease duration, b-interferon use and depression
(coded as ‘yes’/‘no’ variable, with ‘yes’ defined as score of
10 or more on PHQ-9, which corresponds to moderate
depression cut-off). Separately modeled dichotomous out-
come variables included common MS and pain symptoms:
optic neuritis, trigeminal neuralgia, facial pain, occipital
neuralgia, Lhermitte’s sign, cognitive, visual and brainstem
symptoms, restless legs syndrome, painful spasms, body
pain, allodynia, temporomandibular joint syndrome and
analgesic use.
We also used linear regression to assess the impact of
age, gender, disease duration, beta-interferon use and
depression on continuously distributed outcome variables.
To assess the influence of migraine disability on symptom
profiles, we conducted analyses stratified by MIDAS grade
using the four-level disability scoring grading [Grade I,
none–mild (0–5); Grade II, moderate (6–10); Grade III,
severe (11–20); Grade IV ([20)] [20]. Statistical analyses
were carried out using SPSS Statistics v. 17.0 software.
Results
Frequency and characteristics of migraines in MS
patients and AMPP historical controls
The questionnaire was distributed to 225 patients in the
waiting room of NYU-MS Center, and 204 (90%) returned
a completed questionnaire; 64% of patients (131) reported
‘‘a headache within the past year not related to trauma,
infection or medication’’. Of the 131 patients with a
headache, 94 (72%) met ICHD-2 criteria for migraines and
the remaining 37 (28%) for tension-type headaches. There
were ten migraineurs (9.4%) who had a second headache
type that met criteria for tension-type headache. The
patients with migraine and non-migraine headache were
included in the migraine group. In this report, we compare
MS migraineurs (MS-Mig)—this group consisted of 94
patients—with headache-free MS (MS-NH) patients, 73
patients. In general, patients with tension-type headache
and MS had clinical characteristics intermediate between
those of the non-headache controls and the migraine cases.
Data on tension-type headache group will be presented in a
separate publication.
AMPP population consisted of 162,576 responders, of
whom 18,968 individuals met ICHD-2 criteria for migraine
yielding an unadjusted 1-year period prevalence estimate
of 11.7% (5.6% for men and 17.1% for women) [13].
Relative frequency of migraine in MS outpatients was
more than threefold higher than in the AMPP population
controls both for men (18.4 vs. 5.6%, RR = 3.29,
p \ 0.001) and for women (55.7 vs. 17.1, RR = 3.36,
p \ 0.001). Migraine frequency among women with MS
was significantly higher for each age groups (20–29,
30–39, 40–49 and 50 and above) compared to AMPP
controls. There were too few men with both MS and
migraine to allow for age-adjusted analysis.
Thirty-six percent of MS-Mig group had auras. Among
those with aura, most were visual (44.1% of auras), or
visual/sensory (38.2%), and a minority, sensory only
(17.6%). The frequency of migraine with aura and distri-
bution of aura types is nearly identical to that of migrai-
neurs in the AMPP cohort [20]. Migraine disability, as
assessed with MIDAS, did not differ in the MS and in the
AMPP samples: 77% of MS-Mig and 75% of the AMPP
migraineurs had mild-to-moderate migraine-related dis-
ability (MIDAS Grades 1 and 2), while the remainder fell
into migraine Grades 3 and 4. Six patients in the MS cohort
(6.4%) had chronic migraines; all six met criteria for
medication overuse headache.
Demographic characteristics, past medical and family
history
The demographic characteristics, frequencies of co-exist-
ing conditions and family history of MS and migraines in
MS-Mig and MS-NH are presented in Table 1. The two
groups were similar with respect to age (47 ± 13 vs.
43 ± 11 years), and disease duration (13 ± 11 vs.
12 ± 11 years), but MS-Mig had a larger fraction of
women compared to MS-NH (90 vs. 57%, p \ 0.001).
MS-Mig were more likely than MS-NH to report history
of depression (36 vs. 21%, p \ 0.028), and scored higher
on PHQ-9 scales for depression (8.2 vs. 4.7, p \ 0.001).
More MS migraineurs reported a history of mononucleosis
compared to headache-free MS patients (20 vs. 5%,
p \ 0.01), while the rates of other co-existing conditions
were similar.
Family history of MS in first-degree relatives was not
different in the two groups, but family history of migraines
was 2.5 times higher (49%) among MS-Mig than in
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MS-NH (19%), and 3.5 times higher in the MS-Mig with
aura subset (59%) compared to MS-NH.
Episodic neurologic dysfunction in MS migraineurs
and headache-free MS patients
Episodic neurologic dysfunction (END) that lasted more
than 24 h was reported more frequently by MS-Mig group
compared to MS-NH group. In the MS-Mig group, 28%
had three or more ENDs over past year, and only 20% had
none. By contrast, only 10% of MS-NH reported three or
more ENDs and 32% had none. The fraction of patients
with either one or two ENDs was similar in the two groups.
Patients who had never experienced an END likely had
primary progressive form of MS; these patients constituted
a relatively larger proportion of the MS-NH (9%) than of
the MS-Mig (3%) group. The trend towards the increased
number of ENDs was most pronounced in the subset of
patient with migraine with aura (N = 29). In the MS-Mig
with aura subset, 52% reported three or more ENDs over
past year and only 7%, no ENDs.
Pain-related and non-pain-related symptom profiles
The prevalence of specific pain-related symptoms, such as
Lhermitte’s sign, occipital and trigeminal neuralgia, facial
pain, temporomandibular joint pain, spasms, and restless
legs syndrome, was 2–5 times higher in MS-Mig than in
MS-NH (Table 2). Frequent, non-headache-related allo-
dynia was reported by 26% of migraineurs and only 4%
of headache-free patients. Over 20% of the MS-Mig
group required analgesics for non-headache reasons on a
daily basis, compared to 6% in MS-NH group (Table 2).
Over-the-counter medication, NSAIDS and acetamino-
phen, were used for headache by 80 of the 94 migraineurs
(85%).
MS-Mig had considerably more cognitive, psychiatric,
brainstem and visual symptoms, and scored higher on
depression and anxiety scales (PHQ-9, PHQ), fatigue
severity scale and Epworth sleepiness scale than MS-NH
patients (Table 3).
To control for potential confounders, we modeled the
relationship between migraine status and MS related out-
comes using logistic regression to account for age, gender,
disease duration, b-interferon use and depression (defined
as score of 10 or more on PHQ-9). MS related outcomes
associated with migraine at the p \ 0.01 level include tri-
geminal neuralgia, occipital neuralgia, facial pain, painful
spasms, Lhermitte’s sign, temporomandibular joint pain
and non-headache pain. Migraine was not a predictor of
cognitive, brainstem or visual symptoms, restless legs
syndrome, allodynia or daily pain medication use.
Depression was a significant predictor of visual and cog-
nitive problems. Gender was a predictor of painful spasms
and disease duration was a predictor of Lhermitte’s sign
and brainstem symptoms. The results of logistic regression
analyses are presented in Tables 4 and 5 as odds ratios with
95% confidence.
We modeled the relationship of migraine status to a
series of continuous outcomes using linear regression.
These models were adjusted for the same independent
variables used in the logistic models (migraine status, age,
gender, disease duration, b-interferon use and depression).
Migraine was a significant predictor of anxiety and nearly
reached significance for Epworth sleepiness scale
(p = 0.013), while depression and disease duration were
significant predictors of fatigue. Age and gender were not
predictive of any outcome variable.
Importantly, despite the more symptomatic course, the
disability of MS migraineurs, as assessed by Patient-
Derived Disability Score (PDDS) was mild—nearly all
could ambulate without assistive device—and was similar
to those without headache.
Table 1 Demographic characteristics, co-existing medical conditions
and family history in MS-Mig and MS-NH groups
MS-NH MS-Mig p
N 73 94 –
Age in years (mean ± SD) 47 ± 13 43 ± 11 NS
% Female* 57% 90% \0.001
Disease duration in years (mean ± SD) 13 ± 11 12 ± 11 NS
% Interferon beta-1 use 71% 64% NS
Co-existing conditions
Hypertension 12% 15% NS
Diabetes 0% 4% NS
Seizures 1% 4% NS
Syncope 1% 7% NS
Thyroid disease 8% 10% NS
Fibromyalgia 0% 4% NS
Mononucleosis* 5% 20% 0.006
Autoimmune disease 4% 12% NS
Bipolar disorder 4% 3% NS
Anxiety spectrum disorder 8% 16% NS
Depression 21% 36% 0.028
Current smoker 18% 19% NS
Family history
Family history of MS 17% 10% NS
Family history of migraine* 19% 49% \0.001
MS-Mig MS and migraine group, MS-NH MS–no headache group,
NS non-significant
* p \ 0.01
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Side-effects of interferon-beta 1
Interferon-beta (IFNb-1) use was similar in the two groups
(71% for MS-NH and 64% for MS-Mig, p [ 0.1), and the
remainder were using glatiramer acetate or were on no
medication. MS-Mig reported more side-effects to inter-
ferons than MS-NH: 32% of MS-Mig patients had flu-like
symptoms following ‘all or almost all injections’ compared
to only 13% headache-free patients. Furthermore, 34% of
migraineurs on IFNb-1a had a headache within 24 h of the
injection ‘‘always or almost always’’, while the no-head-
ache group did not have post-injection headache.
Radiological characteristics of MS-Mig and MS-NH
groups
Brain MRIs performed within 2 years of the survey were
available for 138 out of 204 patients in the study (67%),
including 65 MRIs of MS-Mig and 49 of MS-NH patients.
The remaining MRIs were of patients with tension-type
headache, and will be discussed in a separate publication.
Table 6 compares the radiographic findings of the two
groups. There were no differences in the number or dis-
tribution of T2 hyperintense lesions or the number of
gadolinium-enhancing lesions in the MS-Mig and MS-NH
groups. There was a trend for more T1 hypointense lesions
in the headache-free group (p \ 0.05).
Discussion
The overall prevalence of headache in our MS sample was
64%, which is within the range reported in several previous
studies [8–11]. Majority of headache seen in MS patients,
72%, were migraines. In comparison with AMPP historical
controls, migraine was threefold more common in MS
Table 2 Painful symptoms and
analgesic use in MS-Mig and
MS-NH groups
* p \ 0.01
MS-NH (%) MS-Mig (%) p OR CI
Brief, shooting pains into jaw* 5 27 \0.001 9.7 2.1–44
Shooting pains into back of head/neck* 11 45 \0.001 9.2 2.7–32
Facial pain* 10 32 0.001 6.6 1.6–27
Temporomandibular joint syndrome* 7 30 \0.001 4.8 1.4–16
Lhermitte’s sign* 18 48 \0.001 5.2 1.9–14
Painful spasms* 29 48 0.012 3.7 1.4–9.6
Restless legs feeling, movement-relieved* 33 57 0.002 2.1 0.87–4.8
Frequent allodynia (not during headache)* 4 26 \0.001 5.3 1.2–23
Daily use of pain medication for non-headache* 6 21 0.006 7.3 1.2–46
Table 3 Non-pain symptoms in
MS-Mig and MS-NH groups
* p \ 0.01
a Double vision, facial
weakness, deafness, abnormal
taste, vertigo
MS-NH MS-Mig p OR CI
Optic neuritis* 49% 77% \0.001 2.8 1.2–6.4
Visual problems interfere with reading 22% 32% NS 0.64 0.25–1.7
Brainstem symptoms*,a 27% 53% 0.001 2.4 1.0–5.7
Cognition ‘‘definitely affected’’ 24% 38% 0.039 1.8 0.67–4.9
Depression score (PHQ-9) 4.7 8.2 \0.001 NA NA
Anxiety score (PHQ) 4.1 6.5 \0.001 NA NA
Fatigue severity score 3.6 5.0 \0.001 NA NA
Hours of sleep per night 6.7 6.8 NS NA NA
Epworth sleep scale score* 5.6 8.1 \0.001 NA NA
Table 4 Predictors of non-pain MS symptoms, according to a multivariate logistic regression model using a forward selection criteria
Optic neuritis Visual problems Cognitive symptoms
No migraine versus migraine 0.300 (0.145–0.621)
No depression versus depression 0.232 (0.103–0.522) 0.197 (0.084–0.458)
No IFNb use versus IFNb use 3.178 (1.427–7.078)
Values are OR and 95% CI after forward selection criterion, p \ 0.01
Age, gender, disease duration, IFNb usage, migraine and depression where not significant predictors of brainstem symptoms; age, gender and
disease duration were not significant predictors of any MS symptoms; p B 0.01
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outpatients. The increased relative frequency of migraine is
consistent with most controlled studies of headache in MS
[2, 3, 6].
Several possible reasons for the association can be
suggested. One possibility is that headaches are directly
attributable to MS (‘secondary headaches’). One consid-
eration that mitigates against this possibility is that MS-
Mig group had an elevated family history of migraine in
comparison to those without migraine. If the excess of
migraine-like headaches were attributable to MS, this result
would not be expected. Furthermore, migraine character-
istics in the MS patient and general population such as the
distribution of migraine-related disability grades (MIDAS
grade), and the ratio of migraine with aura to migraine
without aura were nearly identical in the MS clinic and the
general population [13, 20]. If ‘MS migraine’ were a dis-
tinct entity, it would be more probable that its character-
istics would be distinguishable from those of primary
migraines. Accurate data on temporal relationship between
MS and migraine could help clarify the nature of associa-
tion. To this end, longitudinal studies in which mechanistic
hypotheses will be developed and explored should be
pursued.
Our study is the first to investigate both clinical and
radiographic profiles of MS in patients with and without
migraine. The MS-Mig group had a remarkable increase in
the frequency of both pain-related and non-pain-related
symptoms. MS-Mig group also reported significantly more
episodes of neurologic dysfunction and were likely to have
progressive form of MS, confirming a previously observed
association between migraines and the relapsing form of
MS [9].
We carried out separate analyses comparing headache-
free patients to the subset of MS-Mig with very mild
migraines (MIDAS Grade 1) and more severe migraines
(Grades 2–4). We observed significant increases in ENDs
















































































































































































































































































































































































































































































Table 6 Brain MRI characteristics of MS-Mig and MS-NH groups
MS-NH MS-Mig p
No. of brain MRI 49 65
# of T2 hyperintense lesions 21.5 19.6 NS
# of T2 hyperintense lesions \5 mm 7.0 8.2 NS
T2 hyperintense lesions by location
Periventricular 7.3 5.8
Subcortical 9.9 11.3
Basal ganglia 1.1 0.3
Corpus callosum 2.0 1.3
Brainstem 0.6 0.4
# of T1 gadolinium-enhancing lesions 0.3 0.5 NS
# of T1 hypointense lesions 6.0 3.3 \0.05
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severe migraine subgroup compared to non-headache
group (data not shown). This threshold effect suggests that
the presence of migraine, rather than attack frequency and
severity, accounts for the increased symptom frequency in
MS-Mig subset.
Why do MS migraineurs appear to be so much more
prone to experience new or worsening neurological
symptoms than MS patients who do not have migraines? It
seems unlikely that ENDs represent a direct expression of
migraine aura since most auras subside within an hour and
we specifically enquired about symptoms whose duration
exceeds 24 h. Furthermore, increases in symptom fre-
quency were observed both in MS migraineurs with auras
and those without. Two potential explanations for
increased symptom rate in MS migraineurs may be con-
sidered: (1) migraine may trigger more severe inflamma-
tion in the brain, in which case, increased number of T2
hyperintense lesions, and, especially, of T1 gadolinium-
enhancing lesions, would be expected on brain MRIs of
MS-Mig compared to MS-NH patients; or, (2) migraineurs
may report more symptoms of MS at an equivalent level of
brain pathology, inasmuch as they experience altered pain
perception and have a decreased pain threshold, a phe-
nomenon thought to be due to central sensitization [21–25].
In the latter case, lesion burden on MRI would not be
expected to differ in the two groups.
In our study, T2 and gadolinium-enhancing lesion bur-
den was the same in the two groups, in agreement with a
previous report, in which total number of T2 lesions in MS
migraineurs did not differ from MS non-migraineurs [26].
Since elevated symptom and END rates in MS-Mig did not
translate into greater lesion burden on their MRI, it appears
more plausible that the more elaborate symptomatology in
the migraineurs is not due to more active MS disease
activity in that patient subset, but to their greater suscep-
tibility to manifesting neurologic symptoms. This expla-
nation of increased symptom rates in migraineurs may also
account for our finding that patient’s disability did not
differ between the two groups.
Another hypothesis that is relevant to a subset of mi-
graineurs with aura is that cortical spreading depression of
migraine aura causes unmasking of MS symptoms. If this
were the case, then we would find that migraineurs with
aura (MA) experience even more ENDs than migraineurs
without aura. Indeed, 52% of MA patients reported three or
more ENDs over the past year, compared to 38% in the all-
migraineur group, and 10% in the no-headache group. By
contrast, only 7% of MA patients had no ENDs over the
past year, as compared to 20% of the all-migraineur group
and 32% in the no-headache group (data not shown). Thus,
it is possible that migraine aura may trigger prolonged
neurological deficits with recovery analogous to the
unmasking of deficits in experimental lesions by cortical
spreading depression [27]. One practical ramification of
this observation is that an MS patient who has migraine
with aura may need to be aggressively treated for migraine
in order to prevent not only his migraines, but also pro-
longed episodes of neurological disability that may be
triggered by migraine aura.
We conclude that the greater susceptibility of migrai-
neurs to experience symptoms relating to apperception may
be due to decreased pain and visual discomfort thresholds
in these patients and their proclivity to allodynia [24, 28] or
to induction of ‘pseudoexacerbation’ via cortical spreading
depression. Whether the discrepancy in symptom fre-
quency between and MS migraineurs and non-migraineurs
extends to the non-sensory realms as well (e.g. motor, or
autonomic function deficits, or extraocular movement
abnormalities) is an important question that cannot be
answered with our data.
Migraine is comorbid with depression in the general
population [14–16] and our study extends this association
to MS population. MS migraineurs reported history of
depression at significantly higher rates than headache-free
MS patients, and also scored higher on PHQ-9 scale for
depression. It is important to note that higher END rates
and symptom frequencies in the MS-Mig group cannot be
attributed to higher rates of depression in that group as
migraine was a significant predictor of most pain-related
symptoms even in the logistic regression model that
included depression as one of the dependent variables.
Consistent with most previous reports [6, 11, 30], MS
migraineurs tended to be intolerant of IFNb-1: one in three
experienced a headache ‘always or almost always’ fol-
lowing the injection. Even those with no change in
migraine pattern experienced flu-like symptoms at a sig-
nificantly higher rate than headache-free patients. In clin-
ical practice, it would seem prudent to question all MS
migraineurs who are initiated on b-interferon therapy for
any change in headache pattern and for flu-like symptoms
since these side-effects may have a considerable detri-
mental impact on their quality of life and adherence to
therapy.
One drawback of our study is that it was conducted in a
waiting room of a specialty MS clinic. Although, NYU-MS
Center serves patients from all socio-economic strata, and
the demographics of our patient population are reflective of
MS patients in our area (National MS Society survey,
2007, data on file), clinic patients may be skewed toward
the more severe end of the disability spectrum. Moreover,
studies carried out within medical institutions tend to
overestimate rates of association with comorbid disorders,
a phenomenon known as ‘Berkson’s bias’ [29].
Another potential objection to the study is that the ele-
vated frequency of migraines seen in our patient population
is due, at least in part, to the wide-spread IFNb-1 use at our
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Center, which could trigger and exacerbate migraines [6,
11, 30]. To address this objection, we conducted logistic
regression modeling that was adjusted for interferon use.
Migraine remained a significant predictor of most MS
symptoms in this analysis as well (Tables 4, 5).
Conclusions
Our study demonstrates that relative frequency of migraine
is increased threefold in MS patients attending a specialty
clinic compared to historical population controls. Migraine
disability was considerable among MS patients: nearly one
in four was classified in moderate or severe MIDAS grades.
Migraines in MS are very common, often disabling, yet
potentially treatable. Headache history should therefore be
elicited from all MS patients.
A novel result of our study is a description of ‘MS
migraineur’ who may be distinguished from a headache-
free counterpart by a higher probability of episodic neu-
rologic dysfunction, pain-related symptoms, and higher
rates of depression and anxiety. Population-based, pro-
spective studies with objective documentation of relapses,
cognitive and physical disability, regular MRI brain
examination and controlled for IFNb-1 use, psychiatric
comorbidities, presence of alexithymic trait, are necessary
to clarify the nature of the association between migraine
and MS, and to confirm our finding that MS migraineurs
experience a markedly more symptomatic, but not neces-
sarily more disabling, MS course.
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